Physiologically-based pharmacokinetic (PBPK) modeling has arrived in prime time. This quantitative mechanistic framework, combining physiology with drug information and clinical trial design, has become an integral part of drug discovery and development. PBPK has also gained currency within industry and regulatory agencies. Its applications are numerous, including simulation of pre-clinical, healthy volunteer and special population […]Read More
Author: Matthew Harwood
Matthew obtained his Bachelors and Master’s degrees in Physiology and Human Nutrition from The University of Sheffield and PhD from The University of Manchester. His early career involved undertaking nutritional and enterocyte transport research in Cystic Fibrosis at Sheffield Children’s Hospital. From 2003, Matthew worked at Hope Hospital, Manchester, in association with Pfizer, using ex vivo intestinal tissue to understand region-specific intestinal drug permeability and the role of efflux transporters. From 2007, Matthew has been working for Simcyp Ltd and is principally involved in the development of human PBPK models incorporating membrane transport proteins and pre-clinical transporter protein knock-out PBPK models. From 2011-2015 – As part of an Industrial Fellowship grant from the ‘Royal Commission for the Exhibition of 1851’ with Simcyp Ltd, Matthew completed his PhD ‘Towards a Mechanistic Prediction of Drug Absorption: Investigating Transporter Function Abundance Relationships’ at The University of Manchester under the supervision of Dr Geoff Warhurst and Prof Amin Rostami-Hodjegan. This project aimed to provide human intestinal and cell model transporter data necessary to aid in understanding transporter function and its impact on drug absorption using PBPK models.